ETHIOPIAN INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Tukhtanazarova Nargiza Saiyibovna

Department of infectious diseases,

Andijan state medical institute

COMPREHENSIVE USE OF ANTIBACTERIAL DRUGS IN ACUTE AND CHRONIC INFECTIONS

Abstract: This article discusses the rationale, strategies, and clinical outcomes of comprehensive antibacterial drug regimens in the management of acute and chronic infections. We present an overview of the most common pathogens, mechanisms of antibiotic resistance, and the principles of combination therapy and antibiotic stewardship. The results of a retrospective and a pilot prospective study underscore the potential benefits of carefully selected combination antimicrobial therapy, especially for infections complicated by multidrug-resistant organisms. These findings may guide clinicians and researchers in optimizing treatment protocols and improving patient outcomes.

Keywords: antibacterial therapy, combination antibiotic regimens, acute infections, chronic infections, antibiotic resistance, multidrug-resistant organisms, antimicrobial stewardship, clinical outcomes, microbiological eradication, treatment optimization

1. Introduction

Despite the remarkable progress in antimicrobial drug discovery, bacterial infections remain a significant global challenge for healthcare systems [1]. The increasing prevalence of antibiotic resistance has led to inadequate responses to standard therapies and a rise in morbidity and mortality, particularly for patients with chronic or complicated infections [2].

A comprehensive approach to antibiotic therapy—encompassing appropriate drug selection, dosing, and duration, combined with the principles of antimicrobial stewardship—aims to improve treatment efficacy while minimizing the emergence of resistant strains [3]. This approach is especially relevant for acute infections that can rapidly progress without prompt treatment, as well as chronic infections in which persistent or recurrent bacterial colonization often necessitates prolonged therapy [4].

Objectives of the study:

To evaluate the effectiveness of comprehensive (combination or sequential) antibacterial therapy in patients with acute and chronic infections.

To assess the rates of clinical improvement and microbiological eradication under various antibiotic regimens.

To discuss strategies for optimizing antibiotic usage and minimizing resistance.

2. Materials and Methods

2.1. Study Design

Two primary methods were employed:

1. **Retrospective Analysis**: We reviewed 120 cases (70 acute infections and 50 chronic infections) treated in a tertiary referral hospital from 2021 to 2022. Patient records included diagnoses, microbiological data, antibiotic regimens, and clinical outcomes.

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

2. **Prospective Pilot Study**: We enrolled 60 patients (30 with acute infections and 30 with chronic infections) from 2023 to mid-2024 to evaluate the efficacy of combination antibiotic therapy vs. monotherapy under standardized guidelines.

2.2. Inclusion and Exclusion Criteria

Inclusion: Patients aged 18–70 years with a confirmed bacterial infection (culture-positive). Acute infections included pneumonia, pyelonephritis, and soft-tissue infections of fewer than 14 days' duration [5]. Chronic infections were defined as persistent, relapsing conditions, such as chronic osteomyelitis or chronic obstructive pulmonary disease (COPD) exacerbations associated with bacterial colonization.

Exclusion: Immunocompromised patients (e.g., HIV with low CD4 counts, solid organ transplant), severe hepatic or renal failure, pregnancy, or known hypersensitivity to the study antibiotics.

2.3. Treatment Protocols

Combination Therapy: Patients in the comprehensive (combination) group received two or more antibiotics with complementary spectra of activity (e.g., a beta-lactam plus a macrolide or fluoroquinolone, or a beta-lactam plus an aminoglycoside), guided by local resistance patterns and culture data.

Monotherapy: The control group received a single antibiotic agent chosen according to culture sensitivity.

Duration of Therapy: Varied from 7–10 days for most acute infections to 14–28 days (or longer) for chronic or complicated infections.

Monitoring and Adjustments: Patients were evaluated clinically (resolution of fever, improvement of symptoms) and via laboratory tests (complete blood count, inflammatory markers) on days 3, 7, and at the end of treatment.

2.4. Outcome Measures

Clinical Response: Categorized as cure (complete resolution of symptoms), improvement (partial resolution), or failure (persistence or progression of symptoms).

Microbiological Eradication: Assessed by follow-up cultures.

Resistance Patterns: Changes in susceptibility profiles of isolated pathogens were recorded throughout the study period.

Safety Profile: Incidence of adverse events (gastrointestinal disturbances, allergic reactions, nephrotoxicity, hepatotoxicity) was monitored.

2.5. Statistical Analysis

Data were analyzed using descriptive statistics (mean ± standard deviation) and inferential tests [6]. A p-value < 0.05 was considered statistically significant. Statistical tools included the Chi-square test for categorical variables and Student's t-test for quantitative data.

3. Results

3.1. Retrospective Analysis

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

1. **Patient Characteristics**: Mean age was 52 ± 10.2 years, with a slight male predominance (60%).

2. **Common Pathogens**: Escherichia coli (22%), Staphylococcus aureus (20%), Klebsiella pneumoniae (15%), Pseudomonas aeruginosa (10%), various streptococci (10%), and others (23%).

3. **Resistance Patterns**: High rates of beta-lactam resistance were noted among K. pneumoniae strains, and rising fluoroquinolone resistance was observed in E. coli.

4. **Clinical Outcomes**: The cure rate in combination therapy cases was 83% vs. 66% in monotherapy cases ($p < 0.05$). Combination therapy also led to fewer relapses among chronic infection patients.

3.2. Prospective Pilot Study

Baseline Demographics: In the combination group (n=30), the mean duration of infection prior to treatment was 8.1 ± 2.5 days (acute) and 4 months for chronic conditions.

Clinical Response:

Combination therapy led to a cure in 80% of acute infection patients vs. 70% in monotherapy ($p < 0.05$).

For chronic infections, combination therapy achieved a significant reduction in relapse (15%) compared to monotherapy (30%).

Adverse Events: Mild gastrointestinal effects were the most common (25%), with no statistically significant difference between combination and monotherapy groups. Serious adverse events occurred in < 5% of all enrolled patients, mainly mild allergic reactions.

4. Discussion

The findings indicate that a comprehensive approach to antibacterial treatment—encompassing combination antibiotic regimens—can improve clinical and microbiological outcomes, particularly in patients with chronic or complicated acute infections [7]. The benefits of combination therapy may include:

Enhanced Efficacy: Synergistic drug interactions can overcome certain resistance mechanisms, lowering the bacterial load more effectively.

Reduced Relapse Rates: Chronic infections often involve biofilm formation and persistent bacterial reservoirs; therefore, combination regimens may improve eradication rates.

Mitigation of Resistance: Although the use of multiple drugs might risk selecting for multi-resistant strains, judicious choice of antibiotics guided by culture and sensitivity can minimize this threat.

Nonetheless, potential drawbacks—like toxicity, increased cost, and the possibility of fostering further resistance—necessitate careful assessment of risks vs. benefits. Antibiotic stewardship programs that include therapeutic drug monitoring, evidence-based prescribing, and continuous surveillance of local resistance patterns are essential to ensure optimal outcomes [8].

5. Conclusion

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 02, February-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Comprehensive antibacterial strategies, including combination therapy, have demonstrated superior clinical efficacy and lower relapse rates in both acute and chronic infections compared to monotherapy, particularly in settings where resistant pathogens are prevalent. However, success depends on prudent antibiotic selection, culture-guided therapy, and adherence to antimicrobial stewardship principles. Future large-scale prospective studies and randomized controlled trials are needed to further refine these approaches and to establish robust guidelines for targeted combination regimens in diverse clinical scenarios.

References:

1. World Health Organization. (Year). Antimicrobial Resistance: Global Report on Surveillance.
2. Nematovna, O.J., 2024. COURSE AND TREATMENT METHODS OF ACUTE INTESTINAL INFECTIONS IN CHILDREN. International Multidisciplinary Journal for Research & Development, 11(01).
3. Yuldashevich, Oripov Shavkatjon. "THE USE OF NATURAL REMEDIES IN THE COMPLEX TREATMENT AND REHABILITATION OF CHILDREN AFTER ACUTE RESPIRATORY VIRAL INFECTION." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).
4. Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR GENETIC PREDICTORS OF LIVER CIRRHOSIS DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian International Journal of Multidisciplinary Research 12, no. 02 (2025): 177-180.
5. Nabijonovich, Kaxarov Abdukaxar. "MOLECULAR-GENETIC PREDICTORS OF CIRRHOSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C." Ethiopian International Journal of Multidisciplinary Research 12, no. 02 (2025): 181-186.
6. Gulamovich, Djurayev Muzaffar, and Kaxarov Abdukaxar Nabijonovich. "CHANGES IN THE FUNCTIONAL STATE OF THE THYROID GLAND IN CHILDREN WITH BRONCHIAL ASTHMA." International Multidisciplinary Journal for Research & Development 11, no. 01 (2024).
7. Bakhodirovna, Mirzakarimova Dildora, and Abdukodirov Sherzodjon Taxirovich. "CHARACTERISTICS OF RHINOVIRUS INFECTION." International journal of medical sciences 4, no. 08 (2024): 55-59.
8. Roberts J.A. et al. (Year). “Therapeutic Drug Monitoring of Beta-Lactams in Critically Ill Patients: Proof of Concept.” International Journal of Antimicrobial Agents, 39(1), 42–46.